Not Quite the Same
Regulatory Intermediaries in the Governance of Pharmaceuticals and Medical Devices
Dados Bibliográficos
| ID | 5742017 |
|---|---|
| Autores | Martino Maggetti (0000-0002-7263-3726, autor correspondente), Christian Ewert (0000-0003-2404-5206), Philipp Trein (0000-0001-6217-6675) |
| Ano | 2017 |
| Volume | 670 |
| Fascículo | 1 |
| Páginas | 152-169 |
| Data de publicação | 2017-03-01 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | The Annals of the American Academy of Political and Social Science (JOURNAL) |
| Identificadores do periódico | ISSN: 0002-7162 • E-ISSN: 1552-3349 |
| Editora | SAGE Publications Inc (PUBLISHER) |
| DOI | 10.1177/0002716217691240 |
| OpenAlex | W2560805021 |
| Idioma | EN |
| Citações recebidas | 18 |
| Referências citadas | 27 |
This article compares the role of regulatory intermediaries in the governance of pharmaceuticals and medical devices in Australia and Switzerland. We argue that the creation, selection, and activation of specific intermediaries depend on the organizational capacity of the regulator and on the potential of the intermediary to be captured by the target. To limit the risk of capture of intermediaries where the regulated industries are powerful, regulators tend to keep intermediaries under their control. To do so, the regulator must be well-funded and well-staffed, or supported by its political principal. However, when the target has limited capture potential, regulators will rely more heavily on externalized intermediaries. These intermediaries typically consist of transnational organizations in charge of multiple regulatory issues in several jurisdictions, and can provide unique expertise in an efficient way. Four case studies of the Australian and Swiss regulatory regimes for therapeutic products support this argument
Argument (complex analysis) · Biology · Business · Computer security · Control (management) · Corporate governance · Economics · Industrial organization · Intermediary · Legislature · Management · Political science · Principal (computer security) · Regulator · Biomedical Ethics and Regulation · Computer Science · Finance · Health Systems, Economic Evaluations, Quality of Life · Law · Pharmaceutical Economics and Policy
Managing national expert and advisory committees in the Chinese policy advisory system
Move toward citizens
Bridging disclosure and action
The European regulation of corporate social responsibility
Coordinating monetary policy and macroprudential policy
The engagement of environmental organizations on land policies
Une régulation sous influence ? Capture et conflits d’intérêts
Intermediating climate change
Presidents and intermediaries
Opaque transparency
Regulatory intermediaries and value conflicts in policy implementation
Private regulatory capture via harmonization
Intermediary roles in regulatory programs
Exploring the formal and informal roles of regulatory intermediaries in transnational multistakeholder regulation
Unraveling how intermediary‐beneficiary interaction shapes policy implementation
Theorizing Regulatory Intermediaries
Big Third-Party Certifiers and the Construction of Transnational Regulation
The Consultant's intermediary role in the regulation of molecular diagnostics in the US
Regulating Business by Independent Commission
Lobbying and Policy Change
Preventing Regulatory Capture
The Politics of Regulation
The Politics of Government Decision-Making
Regulation and Regulatory Governance
The logic of comparative social Inquiry
The Annals of the American Academy of Political and Social Science (Annals of the American Academy of Political and Social Science (Paper))
Trading risks for markets
Globalization and Policy Convergence
The Globalisation of Regulation
Risk Versus Risk
Embedded regulation
Regulatory Issue Networks in a Federal System
Case Selection Techniques in Case Study Research
The Conditioning Effects of Policy Salience and Complexity on American Political Institutions
Explanatory Typologies in Qualitative Studies of International Politics
Varieties of Regulatory Capitalism
Groups, the Media, Agency Waiting Costs, and FDA Drug Approval
Handbook of Health Economics
Big Third-Party Certifiers and the Construction of Transnational Regulation
| Obras citantes distintas | 18 |
|---|---|
| Citações por ano | 2 |
| Intervalo de citações | 2017 - 2026 (10) |
| Velocidade de citação | current |
| Altamente citado | Não |
| Tipos de citação | Neutras: 18 |